ClinicalTrials.gg
RecruitingNCT07559318REVIU48Updated Aug 26, 2026

Post-Emergency Optimization of Antibiotic Therapy for Urinary Tract Infection (UTI)

An observational study in Urinary Tract Infections, Antiobiotic Stewardship and Emerging Infectious Disease, sponsored by Centre Hospitalier Intercommunal Creteil. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Centre Hospitalier Intercommunal Creteil · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
330
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Urinary Tract Infections with a site in France — 10 open to participants now, 11 under way, 1 of them phase 3. Urinary Tract Infections · France.

Planned enrollment
8th of 23
330 · median 200
Started
2026
with 3 others
Observational
23 of 58
5 open now
Primary completion
2027-01
later than 6 of 10 live
Registered
57th of 58
by date
Lead sponsor
2 of 58
Centre Hospitalier Intercommunal Creteil

Among the 58 studies in Urinary Tract Infections with a site in France, this one is the 8th largest by planned enrollment of the 23 observational ones that give a count, is one of 4 that started in 2026, is one of 23 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 57th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

10 of the 58 studies in Urinary Tract Infections with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Urinary Tract Infections with a site in France, or all of them as a file.
02

Study summary

Prospective, multicenter, non-interventional study conducted over 6 months, including patients presenting to the emergency department with suspected urinary tract infection managed as outpatients and discharged with or without empiric antibiotic therapy.

Discharge antibiotic prescriptions are reviewed, with subsequent reassessment and optimization of treatment based on urine culture and susceptibility results

Read the detailed description

Urinary tract infections are a frequent cause of emergency department visits, accounting for substantial antibiotic use. Data from the OSCOUR (Organisation de la Surveillance Coordonnée des Urgences) network estimate around 5,000 weekly visits. Resistance rates among Enterobacteriaceae in urine samples are particularly high, largely driven by the widespread use of broad-spectrum antibiotics, especially fluoroquinolones, which are commonly prescribed as empiric therapy. Given their potential for serious adverse effects and their strong selective pressure for resistance, stricter control of their use is warranted, yet remains insufficient.

In current emergency practice, conditions such as pyelonephritis or male urinary tract infections are often treated with broad-spectrum antibiotics that are continued even when pathogens are susceptible to narrower agents. De-escalation to narrower-spectrum therapies would help preserve the microbiota and limit resistance.

This study is a prospective, multicenter, non-interventional observational study conducted over 6 months. It includes patients presenting to the emergency department with suspected urinary tract infections managed on an outpatient basis and discharged with or without empiric antibiotic therapy. Antibiotic treatments are reassessed 48 - 72 hours after inclusion by a physician, allowing for patient follow-up and potential modification of the initial prescription based on urine culture and susceptibility results, in accordance with current guidelines.

The study aims to assess the value of this reassessment strategy in improving antimicrobial stewardship for urinary tract infections in emergency settings and to inform future optimization of clinical practices.

03

Conditions studied

  • Urinary Tract Infections
  • Antiobiotic Stewardship
  • Emerging Infectious Disease

Keywords

  • Urinary tract infection
  • Urine culture and sensitivity tests
  • Antimicrobial stewarship
  • Side effect and adverse event of antibiotics
  • Fluoroquinolones and 3rd-generation cephalosporins
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Inclusion of patients presenting with suspected outpatient urinary tract infections, to the emergency department

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or over
  • Patients presenting at emergency department, with symptoms suggestive of a urinary tract infection suitable for outpatient management (uncomplicated cystitis or cystitis at risk of complications, uncomplicated pyelonephritis or pyelonephritis at risk of complications, male urinary tract infection with or without fever) who have had a urine culture taken

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study
  • Vulnerable person (person under guardianship or trusteeship, minor, person deprived of liberty, person unable to express their refusal)
  • Pregnant women
  • Severe urinary tract infection (sepsis, septic shock or requiring drainage, except for low urinary catheterisation)
  • Hospitalisation for a urinary tract infection or decompensation of another comorbidity
  • Suspected urinary tract infection without a urine culture having been performed
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
330 participants (estimated)
Patient registry
No

Groups and cohorts

  • Suspected of outpatient urinary tract infection

    Inclusion of patients with outpatient urinary tract infection in emergency department

    Other: Adaptation of antibiotics therapy for outpatient urinary infection following emergency care

Interventions

  • OtherAdaptation of antibiotics therapy for outpatient urinary infection following emergency care

    Re assessment of antibiotic therapy at 48 hours based on urine culture results : discontinuation or de-escalation to a narrower-spectrum agent

06

What researchers measure

Primary outcomes

  1. Assess changes in fluoroquinolone and third-generation cephalosporin prescribing in outpatient urinary tract infections following adjustment based on urine culture and susceptibility results.

    Time frame: At 48 hours - 72 hours after the patient inclusion

Secondary outcomes

  1. Incidence (percentage) of adverse effects associated with antibiotics.

    Time frame: At 1 month after the consultation in the Emergency department

  2. Incidence (percentage) of antibiotic prescription savings in the Emergency department for outpatient urinary tract infections (cessation of prescription, shortening of treatment duration and/or narrowing of the spectrum) following the intervention

    Time frame: At 48 hours - 72 hours after the patient inclusion

  3. Assessment of patient satisfaction with medical follow-up via a question asked directly to the patient via a questionnaire (Better if more than 50 percent of patients are satisfied)

    Time frame: At 1 month after the consultation in the Emergency department

  4. Assessment of patients' knowledge of antibiotic resistance via a question asked directly to the patient via a questionnaire (Better if more than 50 percent of patients are satisfied)

    Time frame: At 1 month after the consultation in the Emergency department

07

Study locations

1 of 3 sites recruiting
  • GHSIF
    Melun, France
    Not yet recruiting
    • De Pontfarcy, MD · Contact
  • CH St denis
    Saint-Denis, France
    Not yet recruiting
    • SAYRE, MD · Contact
  • CHIV
    Villeneuve-Saint-Georges, France
    Recruiting
    • Anna BELKACEM, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2027, 7 months after the start.

Of 72 non-industry observational studies under Urinary Tract Infections, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 7 months is below that.

Counting every sponsor, half of 84 studies reached it within 26 months; a quarter within 11 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 30, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07559318
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Jun 1, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Aug 26, 2026

Study contacts

Anna BELKACEM, MD
Contact
anna.belkacem@chiv.fr
01 43 86 21 62
Wissem TOUADI, Resident
Contact
wissemtouadi@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion